Active - does not include patients

Alopecia areata

Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)

Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.

Main Inclusion Criteria: Patients older than 12 years, regardless of prior treatment, currently experiencing extensive (active) disease.

Status: Enrolling patients soon

Start of patient enrollment: August 2024.

Planned completion of new patient enrollment: November 2024.

Testimonials from
our patients

Newsletter

Receive regular notifications about our activities and news in treatments.

Free examinations